long intergenic non-protein coding RNA 518Genealiases: C6orf218 · LENOX
Q-omics provides the consensus-scored LINC00518 profile across patient tissues and cancer cell-line models. LINC00518 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LINC00518 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, LINC00518 RNA expression shows 11,905 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, HNSC, and TGCT as cancer lineages where LINC00518 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00518 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00518 survival associations across molecular data types. LINC00518 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00518 RNA expression–survival associations across cancer types. High LINC00518 expression shows unfavorable associations in LUAD, KIRC, CHOL, PAAD and CESC, but favorable associations in UVM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LINC00518 RNA expression.
This table summarizes LINC00518 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00518. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00518 shows lower tumor expression in KIRC and higher tumor expression in HNSC, LUAD, LUSC, BRCA and COAD. The HNSC box plot shows higher LINC00518 RNA expression in tumor versus normal tissue (log2 FC = +0.516, t-test p < 0.001).
This table shows molecular features associated with LINC00518 in patient tissues and cancer cell lines. In patient samples, LINC00518 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC00518 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN.
